8-KItem 1.02 · Termination of AgreementItem 9.01 · Financial Statements
On Jan 30, 2026 Amgen ($AMGN) entered a Termination Agreement with Kyowa Kirin to end the June 1, 2021…
Filed with the SEC on · Summarized by InvestorsBot
On Jan 30, 2026 Amgen ($AMGN) entered a Termination Agreement with Kyowa Kirin to end the June 1, 2021 License & Collaboration Agreement; termination will become effective upon receipt of regulatory approval. Exhibit 10.1 filed. 🤝📄 #biotech #pharma
Amgen ($AMGN) and Kyowa Kirin agreed to wind down their 2021 collaboration pending regulatory sign-off — investors should monitor related regulatory milestones and potential changes to program rights/royalties. 🧪⚖️ #biotech #pharma
The termination is conditional — no immediate operational change until regulatory approval is received. Details of the Termination Agreement are included as Exhibit 10.1 to the 8‑K. $AMGN 🤝 #pharma #investing